These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 24101112)

  • 21. Systemic therapies in hepatocellular carcinoma.
    Wörns MA; Weinmann A; Schuchmann M; Galle PR
    Dig Dis; 2009; 27(2):175-88. PubMed ID: 19546557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular targeted therapy for hepatocellular carcinoma: bench to bedside.
    Kudo M
    Dig Dis; 2011; 29(3):273-7. PubMed ID: 21829017
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Hepatocellular carcinoma].
    Kondo S; Ueno H; Morizane C; Okusaka T
    Gan To Kagaku Ryoho; 2010 Jul; 37(7):1219-23. PubMed ID: 20647702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group.
    Edmonds K; Hull D; Spencer-Shaw A; Koldenhof J; Chrysou M; Boers-Doets C; Molassiotis A
    Eur J Oncol Nurs; 2012 Apr; 16(2):172-84. PubMed ID: 21641280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan.
    Kudo M; Ueshima K
    Oncology; 2010 Jul; 78 Suppl 1():154-66. PubMed ID: 20616599
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging strategies in the treatment of advanced hepatocellular carcinoma: the role of targeted therapies.
    Lord R; Suddle A; Ross PJ
    Int J Clin Pract; 2011 Feb; 65(2):182-8. PubMed ID: 21235699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathways and targets in hepatocellular carcinoma.
    Psyrri A; Arkadopoulos N; Vassilakopoulou M; Smyrniotis V; Dimitriadis G
    Expert Rev Anticancer Ther; 2012 Oct; 12(10):1347-57. PubMed ID: 23176622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular Targeted Therapies in Hepatocellular Carcinoma: Past, Present and Future.
    Stotz M; Gerger A; Haybaeck J; Kiesslich T; Bullock MD; Pichler M
    Anticancer Res; 2015 Nov; 35(11):5737-44. PubMed ID: 26503994
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early development of sunitinib in hepatocellular carcinoma.
    Zhu AX; Raymond E
    Expert Rev Anticancer Ther; 2009 Jan; 9(1):143-50. PubMed ID: 19105714
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Innovative molecular targeted agents in hepatocellular carcinoma: new gladiators on the arena.
    Ferri J; Dockx Y; Vonghia L; Papadimitriou K; Rasschaert M; Francque S; Peeters M; Rolfo C
    Minerva Chir; 2017 Jun; 72(3):206-218. PubMed ID: 28198177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluating the role of treatment-related toxicities in the challenges facing targeted therapies for advanced hepatocellular carcinoma.
    Palmer DH; Johnson PJ
    Cancer Metastasis Rev; 2015 Sep; 34(3):497-509. PubMed ID: 26250585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted therapy of hepatocellular carcinoma: present and future.
    Chan SL; Yeo W
    J Gastroenterol Hepatol; 2012 May; 27(5):862-72. PubMed ID: 22369685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic therapy and synergies by combination.
    Wörns MA
    Dig Dis; 2013; 31(1):104-11. PubMed ID: 23797131
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel inhibitors in development for hepatocellular carcinoma.
    Wörns MA; Galle PR
    Expert Opin Investig Drugs; 2010 May; 19(5):615-29. PubMed ID: 20374038
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment algorithm for intermediate and advanced stage hepatocellular carcinoma: Korea.
    Choi JY
    Oncology; 2011; 81 Suppl 1():141-7. PubMed ID: 22212948
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Hepatocellular carcinoma: molecular pathogenesis and novel targets for therapy].
    Marquardt JU; Galle PR; Teufel A
    Dtsch Med Wochenschr; 2012 Apr; 137(16):855-60. PubMed ID: 22495921
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sorafenib: activity and clinical application in patients with hepatocellular carcinoma.
    Guan YS; He Q
    Expert Opin Pharmacother; 2011 Feb; 12(2):303-13. PubMed ID: 21226640
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rethinking future development of molecular therapies in hepatocellular carcinoma: a bottom-up approach.
    Villanueva A
    J Hepatol; 2013 Aug; 59(2):392-5. PubMed ID: 23548196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
    Pang RW; Poon RT
    Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic Treatment of Patients with Advanced, Unresectable Hepatocellular Carcinoma: Emergence of Therapies.
    Sun W; Cabrera R
    J Gastrointest Cancer; 2018 Jun; 49(2):107-115. PubMed ID: 29453759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.